Ardsley Advisory Partners LP Decreases Stock Position in Bioceres Crop Solutions Corp. (NASDAQ:BIOX)

Ardsley Advisory Partners LP cut its holdings in Bioceres Crop Solutions Corp. (NASDAQ:BIOX - Free Report) by 32.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,064,614 shares of the company's stock after selling 514,774 shares during the quarter. Ardsley Advisory Partners LP owned 1.70% of Bioceres Crop Solutions worth $6,473,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its position in shares of Bioceres Crop Solutions by 49.3% during the third quarter. JPMorgan Chase & Co. now owns 89,973 shares of the company's stock valued at $708,000 after buying an additional 29,693 shares during the last quarter. Ping Capital Management Inc. boosted its holdings in shares of Bioceres Crop Solutions by 7.3% during the 4th quarter. Ping Capital Management Inc. now owns 44,000 shares of the company's stock valued at $268,000 after acquiring an additional 3,000 shares during the last quarter. Fourth Sail Capital LP grew its stake in shares of Bioceres Crop Solutions by 16.6% in the fourth quarter. Fourth Sail Capital LP now owns 3,698,961 shares of the company's stock worth $22,490,000 after acquiring an additional 527,859 shares during the period. Ballast Asset Management LP raised its holdings in shares of Bioceres Crop Solutions by 23.5% during the fourth quarter. Ballast Asset Management LP now owns 431,887 shares of the company's stock valued at $2,620,000 after purchasing an additional 82,187 shares during the last quarter. Finally, Jump Financial LLC bought a new position in Bioceres Crop Solutions during the fourth quarter valued at approximately $72,000. 17.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BIOX. Lake Street Capital decreased their target price on shares of Bioceres Crop Solutions from $13.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Oppenheimer dropped their target price on Bioceres Crop Solutions from $8.00 to $7.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 22nd. Finally, Canaccord Genuity Group cut their price target on Bioceres Crop Solutions from $7.00 to $6.50 and set a "buy" rating for the company in a research note on Thursday, February 13th. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $8.63.

Bioceres Crop Solutions Stock Performance

NASDAQ:BIOX opened at $4.59 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.96 and a current ratio of 1.33. The stock has a 50-day simple moving average of $4.37 and a two-hundred day simple moving average of $5.73. The firm has a market capitalization of $287.84 million, a PE ratio of 229.61 and a beta of 0.40. Bioceres Crop Solutions Corp. has a 52-week low of $3.51 and a 52-week high of $13.18.

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.

Want to see what other hedge funds are holding BIOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioceres Crop Solutions Corp. (NASDAQ:BIOX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.